1. Volume 55, Issue 6, Pages 1269-1277 (June 2009)
Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological Group 
Fernando E.C. Calais da Silva, Aldo V. Bono, Peter Whelan, Maurizio Brausi, Anton Marques Queimadelos, Jose A. Portillo Martin, Ziya Kirkali, Fernando M.V. Calais da Silva, Chris Robertson 
European Urology 
Volume 55, Issue 6, Pages (June 2009)
DOI: /j.eururo
Copyright © 2009 European Association of Urology Terms and Conditions

2. Fig. 1
Kaplan-Meier curves for the time to any progression and time to death (continuous arm=dotted lines; intermittent arm=solid lines). The numbers along the bottom detail the numbers of patients, separately for each arm of the study, still in active follow-up at the time of publication (continuous therapy, top row; intermittent therapy, bottom row). The p values are for the log-rank test. (a) Time to any progression. (b) Overall survival. (c) Overall survival by prostate-specific antigen (PSA) level at randomisation: Int 0–2=intermittent therapy, randomisation PSA level 0–2 ng/ml; Int 2-4=intermittent therapy, randomisation PSA level 2–4 ng/ml; Int 4+=intermittent therapy, randomisation PSA level ≥4 ng/ml; Cont 0–2=continuous therapy, randomisation PSA level 0–2 ng/ml; Cont 2–4=continuous therapy, randomisation PSA level 2–4 ng/ml; Cont 4+=continuous therapy, randomisation PSA level ≥4 ng/ml. (d) Overall survival by metastatic status: Int M0=intermittent therapy, M0; Int M1=intermittent therapy, M1; Cont M0=continuous therapy, M0; Cont M1=continuous therapy, M1. The p values are for the log-rank tests in the separate strata.
European Urology  , DOI: ( /j.eururo )
Copyright © 2009 European Association of Urology Terms and Conditions